Breast Cancer Research and Treatment **39**: 353-354, 1996.

Author index, Volume 39

Adhikarakunnathu S 293
Adlercreutz H 335
Adriaansen-Slot GEJ 139
Aldaz CM 177
Amundadottir LT 119
Andersen KW 321

Balsara BR 343
Berghorn M 165
Berland E 327
Bhat AV 343
Bhisey AN 343
Bier B 165
Birtwisle-Peyrottes I 147
Blijham GH 307
Blijham GH 239
Böcker W 165
Bolla M 327
Bonadonna G 285
Bontenbal M 307
Bottari SP 327
Brambilla C 285
Brünner N 87
Burrows FJ 241

Calaf G 221
Caldani C 147
Callahan R 33
Campbell IR 155
Campora E 235
Caraceni A 285
Chambaz 327
Chedin M 327
Chen T 177
Clarke R 1,69
Colonna M 327
Conte PF 235
Cullen K 87

Damen CA 239
Das BC 197
Daskal I 221
de la Rochefordière A 275
de Vries EGE 307
Demicheli R 285
Dhingra K 177
Dickson RB 103,119
Dolsma WV 307
Dow KH 261
Dünser M 165

Ejlertsen B 321
Ekse D 335
Elliott RL 349
Estrada S 221
Ettore F 147

Faaland CA 293
Ferrari L 285
Ferrell BR 261
Fluck MM 45

Giannessi PG 235
Gilchrist KW 203
Gopalkrishna V 197
Green JA 155
Griffioen AW 239
Grimes RW 187
Groenewegen G 239
Gulasekaram P 261

Hagemann H-A 165
Hammond JM 187
Harris CP 203
Haslam SZ 45
Head JF 349
Hedau ST 197
Heinrichs S 165
Helle SI 335
Hortobagyi G 177
Hu Y-H 315
Hupperets PSGJ 307

Javier R 45
Johannessen DC 335

Kalman E 221
Kelly V 155
Kern FG 103
Kharbanda S 103
Kristensen B 321
Kurebayashi J 103
Kuroishi T 315

Lah TT 221
Langer D 165
Lauritzen JB 321
Le-Nir CC-S 275
Lebesque JV 307
Leigh S 261
Lidereau R 275
Lippman ME 103
Lönn S 213
Lönn U 213
Lønning PE 335
Lowther GW 247
Ly J 261

Mandal AK 197
Manni A 187
Marron-Charriere J 327
Martini C 285
Matsushita Y 315
McCallum HM 247
McLeskey SW 103
Meisner LF 203
Merlino G 119
Moliterni A 285
Moll J-L 147
Morrow M 351
Mosseri V 275
Mouridsen HT 321
Mulder NH 307

Nagata C 315
Naso C 235
Nilsson B 213
Noguès C 275

Öfner D 165

Pouillart P 275
Price JE 93
Pronzato P 235

Rao RS 343
Repetto L 235
Rijksen G 139
Rodenhuis S 307
Rosso R 235
Rostagno P 147
Rostaing-Puissant B 327
Russo I 7
Russo J 7,221

Sahin A 177
Salero E 221
Samson W 203
Schmid KW 165
Scholl SM 275
Schouten HC 307
Sharma JK 197
Shenk T 45
Shimizu H 315
Shinde BG 221
Singh UR 197
Slater AJ 155
Smith GH 21
Sneige N 177
Sodhani P 197
Somers R 221
Spang-Thomsen M 87
Spinelli I 235
Staal EJ 139
Stanley ER 275
Stenkvist B 213

Terenziani M 285
Thomas T 293

Thomas TJ 293
Thorpe PE 241

Varughese T 343
Vigani A 235

Xing W-R 203

Zambetti M 285
Zhang L 103

Breast Cancer Research and Treatment **39**: 355-358, 1996.

Subject index, Volume 39

adenovirus
  human adenovirus type 9 in rat mammary fibroadenoma model 57-67
AgNORs (silver-staining nucleolar organizer regions)
  as a prognostic factor 165-176
allelotype
  from single paraffin sections by microsatellite length polymorphism analysis 177-185
angiogenesis inhibitors
  AGM 1470 slows FGF-4/*lacZ*-transfected MCF-7 cells in nude mice 103-117
animal models of breast cancer
  overview 1-6
  special issue 1-136
antiestrogen
  ER during cell cycle in tamoxifen-resistant MCF-7 xenograft 147-154
antiestrogen
  see also tamoxifen
autologous bone marrow transplantation
  in high-dose chemotherapy during complete remission 307-313

beta galactosidase
  FGF-4/*lacZ*-transfected MCF-7 in nude mouse metastasis model 103-117
biopsy technique
  stereotactic core needle biopsy vs. excisional biopsy — discussion 349-351
birth season
  no association with breast cancer risk in Japan 315-319

c-erbB-2 oncogene
  see HER-2/*neu*
carcinogenesis
  DMBA rat mammary tumor model 7-20
cathepsins
  D, B, and L in *ras*-transformed human breast epithelial cells
cell cycle genes
  in transgenic mouse models of breast tumorigenesis 119-135
cell lines
  from primary breast tumor cultures, in defined medium 247-259
chemotherapy
  doxorubicin vs. mitoxantrone, both with cytoxan and vincristine 155-163
  high-dose, in complete remission 307-313
  vinorelbine as an active, non-cross-resistant drug in advanced disease 285-291
chromosome in situ hybridization
  in interphase cytogenetic analysis of specific genes and chromosome copy number 177-185
colony-stimulating factor CSF-1
  in serum, as an indicator of early metastatic relapse 275-283
cytogenetics
  in a case of prepubertal breast cancer 343-347
cytokines
  serum CSF-1 as an indicator of early metastatic relapse 275-283

DMBA rat mammary tumors
  as an animal model of breast cancer 7-20
doxorubicin
  vs. mitoxantrone, both with cytoxan and vincristine 155-163
ductal progenitors
  distinct from lobular progenitors 21-31

endocrine therapy
  no improvement of tamoxifen treatment response by interferon-beta 235-238
  see also tamoxifen
endocrinology
  studies in xenografts in different immune-deficient mice 68-86
endothelial cells
  endoglin/CD 105 as a treatment target 239-242
estrogen receptor
  during cell cycle in MCF-7 147-154
  in cell lines from breast tumor primary cultures 247-259

estrogen therapy
and loss of IGF-II mRNA in T61 xenograft model 87-92
estrogens
postmenopausal plasma levels and shorter disease-free interval 335-341

fibroadenomas
generated by human adenovirus type 9 in rat mammary gland 57-67
fibroblast growth factors
FGF-4/*lacZ*-transfected MCF-7 cells in nude mouse metastasis model 103-117
fine-needle aspirates
PCR detection of HER-2/*neu* amplification 213-220
fluorescent in situ hybridization (FISH)
detection of HER-2/*neu* amplification in early-onset breast cancer 203-212

gene amplification
FISH detection of HER-2/*neu* amplification in early-onset breast cancer 203-212
PCR detection of HER-2/*neu* amplification in fine-needle aspirates 213-220
genetic evolution
allelotype analysis technique from single microdissected paraffin sections 177-185
genetics
detection of genes involved in tumor progression in MMTV model 33-44

HER-2/*neu* oncogene
FISH detection of amplification in early-onset breast cancer 203-212
PCR detection of amplification in fine-needle aspirates 213-220
high-dose chemotherapy
during complete remission 307-313
hormone dependence
estrogen dependence of adenovirus type 9 generated rat mammary tumors 57-67
hormone replacement therapy
postmenopausal plasma estrogens and shorter disease-free interval 335-341
human papillomavirus (HPV)
complete absence of HPV types 16 and 18 DNA in breast cancer (PCR) 197-202

IGF binding protein 3
clearance/proteolysis inhibited by IGF ligands 187-196
IGF-II
mRNA loss with endocrine therapy in T61 xenograft model 87-92
image analysis
of ER during cell cycle in MCF-7 cells and xenografts 147-154
immunobiology
of different immune-deficient mice as xenograft recipients 69-86
immunodeficient mice
in metastasis model 93-102
xenograft models of breast cancer 97-92
see also nude mice
insulin-like growth factors
-see IGFs
int genes
and tumor progression — MMTV mouse model 33-44
in transgenic mouse models of breast tumorigenesis 119-135
interferon-beta
no improvement of tamoxifen treatment response 235-238
internalization
not required for proteolytic clearance of IGFBP-3 by MCF-7 cells 187-196
invasion
cathepsins D, B, and L in c-Ha-*ras*-transformed human breast epithelial cells

lobular progenitors
distinct from ductal progenitors 21-31
lysosomal proteases
cathepsins D, B, and L in *ras*-transformed human breast epithelial cells

mammary epithelial development
separate ductal and lobular progenitor cells 21-31
mammary fat pad
orthotopic injection of MDA-MB-435 cells in metastasis model 93-102
MCF-7 human breast cancer cells
FGF-4/*lacZ*-transfected MCF-7 in nude mouse metastasis model 103-117

MCF-7 human breast cancer cells *(cont.)*
inhibition of growth and polyamine biosynthesis by S-adenosyl methionine decarboxylase inhibitors 293-306
estrogen receptor during cell cycle 147-154
IGFBP-3 clearance inhibited by IGF ligands 187-196
MDA-MB-435 cells
in metastasis model 93-102
metastasis
serum CSF-1 as an indicator of early metastatic relapse 275-283
metastasis model
MDA-MB-435 cells injected in the nude mouse mammary fat pad 93-102
FGF-4/*lacZ*-transfected MCF-7 cells in nude mice 103-117
microdissection
in allelotype analysis from single paraffin sections 177-185
mitoxantrone
vs. doxorubicin, both with cytoxan and vincristine 155-163
MMTV (mouse mammary tumor virus) infected mice
model for detecting genes in tumor progression 33-44
morphogenesis
separate ductal and lobular progenitor cells 21-31
mouse cell transplantation model
showing separate ductal and lobular progenitor cells 21-31
mouse models of breast cancer
human xenografts in nude, *scid*, *bg/nu*, and other mouse recipients 69-86

nucleolar organizer regions (AgNORs)
as a prognostic factor 165-176
nude mice
and mouse polyomavirus mammary tumor model 45-56
FGF-4/*lacZ*-transfected MCF-7 cells in metastasis model 103-117

oncogenes
E4 ORF1 adenovirus protein 57-67
in transgenic mouse models of breast tumorigenesis 119-135
oncogenesis
by polyomavirus in mouse mammary gland 45-56
osteoporosis
no reduction in femoral fractures by tamoxifen 321-326

papillomavirus
complete absence of HPV types 16 and 18 DNA in breast cancer (PCR) 197-202
PCR
complete absence of HPV types 16 and 18 DNA in breast cancer 197-202
in detection of HER-2/*neu* amplification in fine-needle aspirates 213-220
pentosan polysulfate
slows FGF-4/*lacZ*-transfected MCF-7 cells in metastasis model 103-117
phyllodes tumor
generated by human adenovirus type 9 in rat mammary gland 57-67
polyamines
inhibition of MCF-7 growth and polyamine biosynthesis by S-adenosyl methionine decarboxylase inhibitors 293-306
polymerase chain reaction
see PCR
polyomavirus
mouse mammary tumor model 45-56
prepubertal breast cancer
cytogenetic analysis of a case 343-347
primary breast tumor cultures
in defined medium 247-259
prognostic factors
cytosolic tyrosine kinase activity 327-334
FISH detection of HER-2/*neu* amplification 203-212
increased AgNORs (silver-staining nucleolar organizer regions) and early relapse 165-176
PCR detection of HER-2/*neu* amplification in fine-needle aspirates 213-220
serum CSF-1 as an indicator of early metastatic relapse 275-283
protein tyrosine kinase
see tyrosine kinase
psychological issues
quality of life study among long-term breast cancer survivors 261-273

quality of life
study of long-term breast cancer survivors 261-273

ras oncogenes
in transgenic mouse models of breast tumorigenesis 119-135
cathepsins D, B, and L in c-Ha-*ras*-transformed human breast epithelial cells
risk factors
no association of birth season with breast cancer risk in Japan 315-319

S-adenosylmethionine decarboxylase inhibitors
inhibition of growth and polyamine biosynthesis in MCF-7 cells 293-306
serum markers
CSF-1 as an indicator of early metastatic relapse 275-283
serum-free medium
breast tumor primary cultures 247-259
special issue
animal models of breast cancer 1-136
spermine
inhibition of MCF-7 growth and polyamine biosynthesis by S-adenosyl methionine decarboxylase inhibitors 293-306
src tyrosine kinase
ELISA assay with cdc2 peptide substrate 139-145
stereotactic core needle biopsy
vs. excisional biopsy — discussion 349-351

tamoxifen
ER during cell cycle in resistant MCF-7 xenograft 147-154
no improvement of treatment response by interferon-beta
no reduction in femoral fractures 321-326
terminal end buds
as a target for carcinogenesis in rat model 7-20
tissue culture
long-term culture of primary breast cancer in defined medium 247-259
transgenic mice
bearing the mouse polyomavirus middle T antigen 45-56
in breast cancer models, review 119-135

tumor evolution
in the DMBA rat mammary tumor model 7-20
MMTV-infected mice as a model for detecting relevant genes 33-44
tumorigenesis
transgenic mouse models 119-135
tyrosine kinase
as a possible prognostic factor 327-334
ELISA assay for src-family kinase 139-145

vinorelbine
as an active, non-cross-resistant drug in advanced disease 285-291
viral oncogenes
middle T antigen in mouse polyomavirus mammary tumor model 45-56

xenografts
as breast cancer models in different recipient mice 69-86
T61 human tumor model of estrogen therapy 87-92